Arcturus Therapeutics Inc.

ARCT | NASDAQ

Price Alert Chart Builder DCF Calculator

$14.48

-$0.21 (-1.43%)

Sep 22, 2026, 11:07 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-1.43%

(1D)

Rating

Updated: Aug 25, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $411.57M

1D Range

13.88 14.69

52W Range

5.50 24.17

Valuation (TTM)

PE -4.41

PB 2.43

EV/EBITDA -3.00

Valuation (NTM)

Forward PE N/A

Forward PEG -0.60

Price Target $41

Cash Flow

FCF Yield -22.1%

SBC Adj. FCF Yield -28.2%

SBC Impact -27.5%

Margins

Gross Margin 83.2%

Operating Margin -433.4%

FCF Margin -388.6%

Growth (CAGR)

Revenue 3Y | 5Y -55.2% | 22.3%

Dil EPS 3Y | 5Y -14.0% | 3.5%

FCF 3Y | 5Y -14.0% | -15.2%

Returns

ROA -41.6%

ROE -46.5%

ROIC -53.0%

Financial Health

Net Cash

$191.48M

Current Ratio 5.88

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respira...

Sector Healthcare

Industry Biotechnology

Employees 109

IPO Date May 21, 2013

Website arcturusrx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 9, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$41

Upside

+183.15%

Buy (5)

Hold (2)

Sell (0)

Analyst Details ➞